- Home
- TPVG vs KOD Comparison
TPVG vs KOD Comparison
Compare TPVG & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPVG
- KOD
- Stock Information
- Founded
- TPVG 2013
- KOD 2009
- Country
- TPVG United States
- KOD United States
- Employees
- TPVG N/A
- KOD N/A
- Industry
- TPVG Other Consumer Services
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TPVG Consumer Discretionary
- KOD Health Care
- Exchange
- TPVG Nasdaq
- KOD Nasdaq
- Market Cap
- TPVG 253.9M
- KOD 259.6M
- IPO Year
- TPVG N/A
- KOD 2018
- Fundamental
- Price
- TPVG $6.72
- KOD $3.50
- Analyst Decision
- TPVG Hold
- KOD Hold
- Analyst Count
- TPVG 6
- KOD 3
- Target Price
- TPVG $6.55
- KOD $9.00
- AVG Volume (30 Days)
- TPVG 269.0K
- KOD 499.6K
- Earning Date
- TPVG 05-07-2025
- KOD 05-14-2025
- Dividend Yield
- TPVG 17.91%
- KOD N/A
- EPS Growth
- TPVG N/A
- KOD N/A
- EPS
- TPVG 0.93
- KOD N/A
- Revenue
- TPVG $101,260,000.00
- KOD N/A
- Revenue This Year
- TPVG N/A
- KOD N/A
- Revenue Next Year
- TPVG $5.37
- KOD N/A
- P/E Ratio
- TPVG $7.24
- KOD N/A
- Revenue Growth
- TPVG N/A
- KOD N/A
- 52 Week Low
- TPVG $5.53
- KOD $1.92
- 52 Week High
- TPVG $9.70
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- TPVG 59.79
- KOD 46.34
- Support Level
- TPVG $5.87
- KOD $2.81
- Resistance Level
- TPVG $6.69
- KOD $4.30
- Average True Range (ATR)
- TPVG 0.21
- KOD 0.49
- MACD
- TPVG 0.11
- KOD -0.10
- Stochastic Oscillator
- TPVG 98.26
- KOD 29.61
About TPVG TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp is a closed-end, non-diversified management investment company. Its investment objective is to maximize its total return to stockholders in the form of current income and, to a lesser extent, capital appreciation. The fund focuses on companies operating in the fields of biofuels, business applications software, wireless communications equipment, e-commerce, clothing and accessories, conferencing equipment and services, personal goods, financial institutions and services, entertainment, mixed retailing, and healthcare services. Geographically, all the operations of the firm function through the region of the United states.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.